
Dr. Sun walks through NIVOPOSTOP: adjuvant nivolumab added to cisplatin–radiation in surgically resected locally advanced head and neck cancer with high-risk features.

Dr. Sun walks through NIVOPOSTOP: adjuvant nivolumab added to cisplatin–radiation in surgically resected locally advanced head and neck cancer with high-risk features.

The primary outcome in this study, as defined, was disease-free survival as assessed by the treating investigator — the physician giving the nivolumab if the patient was randomized to that arm.

We’re going to transition a bit to your space, but we’re also going to be talking about the curative-intent setting.